| 2020 is set to be a pivotal year for the gene therapy field. Multiple late-stage programs are on the brink of approval and existing infrastructure is being tested to breaking point as academic promise is transformed into large-scale commercial reality.
Against this backdrop of innovation, the 4th Annual Gene Therapy for Rare Disorders (March 30 â April 2, Boston) is the niche, focused meeting that will unite the industry leaders pioneering this rapidly evolving space, all under one roof.
Access the official event guide to learn more.
Across four packed days, youâll immerse yourself in the gene therapy world with over 700 like-minded peers.
Four brand-new elements of the program for 2020: - Commercial Insights Directly from Payers and ICER
Donât just speculate about how payers and groups like ICER evaluate gene therapies, learn directly from them and ask your burning questions to Harvard Pilgrim Healthcare Institute, ICER, Blue Cross Blue Shield and MIT NEWDIGS
- In-Depth Immunogenicity & Re-Dosing Insights
Address the elephant in the room and prepare yourself for future re-dosing challenges by exploring the novel approaches Spark Therapeutics, Selecta Biosciences and the University of Florida are developing
- Insights into Large-Scale Manufacturing & Gene Therapy Facilities
Ensure your process development approach is scalable and that you have appropriate facilities to handle large-scale manufacturing by learning from Pfizer, BioMarin and Sanofi
- Gain the International Regulatory Perspective
Align your gene therapy development work with the actual requirements of the FDA and CFDA, to streamline your approach while ensuring regulatory work is robust
This Friday, January 24 is your last chance to save up to $600 on your ticket for the meeting â secure your place now.
I hope to meet you in Boston in March.
Kind regards,
David
David Snowdon
Program Director
Hanson Wade
 |
